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Abstract
Background: Most cases of hypertension can be effectively treated with lifestyle changes together with
medications, but within this population lies a group with more difficult to treat hypertension—those with apparent
treatment-resistant hypertension (aTRH). The American Heart Association and the UK National Institute for Health
and Care Excellence have both highlighted the need for further research into the prognosis of patients with
resistant hypertension, both apparent and true.
Methods: In 16 practices affiliated to a university research network, 646 patients had been identified with apparent
treatment-resistant hypertension. To inform a planned full cohort study of these patients, we conducted a feasibility
study within three practices to determine participation of practices and patients, availability of outcome measures
and data collection times.
Results: All three practices fully participated and 205/210 (98%) patients were followed up for a median of
23 months. Thirty-five outcome events of interest occurred—the most common was the new onset of retinopathy
(9 cases). Eight percent (17/210) had the main composite outcome of death or serious incident cardiovascular
event. Of the six patients who died, identification of cause of death was possible from practice records in five; the
national General Register Office was successfully used for the final patient. There were 123 admissions, both day
and overnight, recorded in 94 individual patients. Average manual systolic blood pressure measurements improved
from baseline by 5 mmHg to 138 (SD 19) mmHg; diastolic remained the same at 75 (SD 12) mmHg. Average eGFR
increased from 58.8 (SD17.4) to 66 (SD19.7) mls/min/1.73m2. The average time for data collection per patient was
12 mins.
Conclusions: This study demonstrates that the proposed methodology for a full cohort study within general
practice of patients with apparent treatment hypertension is both acceptable to practices and feasible. An
adequately powered subsequent follow-up study of the entire cohort appears possible.
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Background
Arterial hypertension accounts for, or contributes to,
62% of all strokes and 49% of all cases of heart disease
[1]. Most cases of hypertension can be effectively treated
with lifestyle changes and/or medications, but within
this population lies a group with more difficult to treat
hypertension—those with treatment-resistant hyperten-
sion (TRH). TRH is defined as high blood pressure in a
patient taking three or more differing groups of anti-
hypertensive medications (one of which must be a diur-
etic type medication) or any patient who is taking four
or more anti-hypertensive medications irrespective of
blood pressure level [2]. Doses should be the optimal
tolerated doses for each particular medication, lifestyle
issues should also be addressed and white coat hyperten-
sion needs to be examined by ambulatory blood pressure
monitoring (ABPM). When issues of dosing, medication
adherence and white coat hypertension have not yet
been ruled out, the term apparent treatment-resistant
hypertension (aTRH) is utilised.
A recent meta-analysis of the prevalence of aTRH for
a total population of 961,035 patients with diagnosed
hypertension yielded prevalences for observational stud-
ies and trials respectively of 13.7 and 16.3% [3]. Individ-
ual study prevalence varied between 4.2 and 25.4%.
Having established that resistant hypertension is appar-
ently common, a key next step is to determine how im-
portant it is. Multiple cross-sectional studies comparing
patients with aTRH to those without have suggested in-
creased frequency of target organ damage and later car-
diovascular complications [4]. In a key study, Daugherty
[5] provided the best evidence to date with an outcome-
based study on the longitudinal assessment of a large co-
hort of patients with aTRH (n = 3960). She found a 50%
increase in cardiovascular events (largely attributable to
development of chronic kidney disease) compared to
those whose blood pressure was controlled on three
medications. This impressive study is however a retro-
spective study of electronic insurance data with no as-
sessment of ABPM or dosing and limited assessment of
adherence. Sim also confirmed a possible increased car-
diovascular risk associated with aTRH in 60,327 patients
[6]. Patients with resistant hypertension, compared to
those without, had significantly increased hazard ratios
for stroke and mortality, respectively, of 1.14 (95% CI
1.10–1.19) and 1.06 (95% CI 1.03–1.08). However, Irvin
[7] in retrospectively comparing similar groups found no
significant increased risk of stroke but an increased risk
for mortality. These studies, utilising large electronic
databases, had large patient numbers but limited assess-
ment of adherence, dosing and white coat hypertension.
The American Heart Association [8] and the UK
National Institute for Health and Care Excellence [9]
have both highlighted the need for further high-quality
prospective research into the prognosis of patients with
resistant hypertension.
Previously, in a cross-sectional study of 6691 patients
with hypertension in 16 Irish general practices, we iden-
tified 646 patients in Irish general practice with aTRH,
whose files were individually reviewed and in whom
pseudo-resistance was also examined [10]. These 646
patients therefore represent a unique general practice
cohort of patients with comprehensive assessment for
true treatment-resistant hypertension. It is planned to
conduct a future prognostic cohort study of these
6691patients to compare those with apparent treatment-
resistant hypertension and those with essential hyperten-
sion. In anticipation of this, we conducted a feasibility
study to determine participation of practices and
patients, availability and frequency of outcome measures
and data collection times required.
Methods
Design and setting
The original cross-sectional study has been comprehen-
sively described elsewhere [10]. In short,16 general prac-
tices in the university-affiliated research network
WestREN, representative of the Irish population, partici-
pated [11]. All used the same practice software system
(Socrates®) and the International Classification for Pri-
mary Care (ICPC-2) coding of chronic diseases. Ireland
does not have universal registration with a general prac-
titioner. All patients aged over 70 years, or below 6 years,
and those below defined income levels receive free gen-
eral practitioner care. These patients represent almost
40% of the general population and are registered with
the Primary Care Reimbursement Service (PCRS; http://
www.hse.ie/eng/staff/PCRS/) with the remainder being
described as private patients and able to see any general
practitioner. We therefore included in the cross-
sectional sample all PCRS patients and those private
patients who had attended the practice in the last year.
Each practice ran a standard ATC drug search iden-
tifying patients on any possible hypertensive medica-
tions as defined by the British National Formulary
69th Edition (https://www.amazon.co.uk/British-National-
Formulary-BNF-69/dp/0857111566). Two researchers (PH
and MC), in conjunction with the practices, then reviewed
the record of each individual patient who was reported as
being on one or more hypertensive medications and
determined if they were hypertensive or not, had a
previous ambulatory blood pressure measurement or not
and what hypertensive medications and doses they were
currently receiving. This work fulfilled for the general
practitioners, the Irish Medical Council requirement, to
conduct an annual audit.
Patients were then identified as being hypertensive if
this diagnosis was recorded in clinical notes by their GP
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or if they had the appropriate diagnosis code recorded in
the patient file (i.e. International Classification of Pri-
mary Care codes for hypertension-K87, K87). No start
date for the diagnosis was recorded; this is not therefore
an incident cohort.
Recruitment
For this feasibility study, three practices were pragmatic-
ally chosen from the original 16 to reflect practice diver-
sity—one was small and rural, one a medium and rural
practice and one a large and mixed urban-rural practice.
All 16 practices used the same practice software system
(Socrates®) to store patient data, were located within 1-h
travel of the university and had a mix of PCRS and pri-
vate patients.
There were no incentives provided to these practices to
participate; however, a stipend of €1000 was paid to all 16
practices when assembling the initial cohort as an acknow-
ledgement for the extra workload involved. All 210 patients
in these three practices were eligible to participate.
Data collection
In each of the three practices, a manual review of each
patient’s individual patient electronic record was per-
formed by two trained researchers (HK and MC).
Both researchers participated in seminars on resistant
hypertension. Training was also provided on how to use
the practice software system (Socrates®) and more specif-
ically on how to search for the data required. Both
researchers worked in one practice together, and then,
HK completed the other two practices, recording any
issues for later clarification.
Outcomes
We recorded the time spent in each practice for data
collection, the proportions of patients whose records
could be successfully accessed and who had an outcome
of interest.
The proposed main composite outcome measurement
is the same as that used by Daugherty [5]: all-cause mor-
tality and incident cardiovascular events which include
nonfatal myocardial infarction, heart failure, stroke or
chronic kidney disease (CKD). Identification of cause of
death was primarily through hospital or physician no-
tices in patient’s files or through death certs. Where
these were not informative, the national online General
Register Office was utilised https://www.welfare.ie/en/
Pages/Apply-for-Certificates.aspx.
Identification of the specified conditions are based on
diagnosis codes, hospital correspondence and lab data.
Patients are described as having diabetes if they have
ICPC codes T89 (diabetes insulin-dependent) or T90
(diabetes non-insulin-dependent) or are taking insulin or
oral hypoglycaemic agents. Patients are described as
having CKD if an estimated glomerular filtration rate
(eGFR) less than 60 mls/min/1.73m2 was recorded.
Patients are described as having cardiac failure if they
have ICPC code K77 or are noted to have this condition
on hospital correspondence.
Recent blood pressure (BP) readings (manual and 24-h
ambulatory) were also recorded, as was anti-
hypertensive medication and doses. Hospital admissions
and diagnoses were identified by discharge summaries.
Day admissions largely involved medical or surgical
assessment unit visits, angiograms or specialised testing
requiring a ward admission. We did not include patients
presenting for simpler tests such as echocardiograms or
stress tests as a day admission.
Power calculation
Table 3 illustrates the outcome events for patients with
apparent treatment-resistant hypertension over a median
of 1.9 years. Daugherty et al., for their main composite
outcome over 3.8 years, found that 18 and 13.5% of
patients with apparent treatment hypertension and sim-
ple hypertension respectively had the outcome. 8.3% of
our cohort had the equivalent of Daugherty’s composite
outcome and 17% a combination of all cardiovascular
events. This suggests that a review of our entire original
cohort over 4 years will result, at least, in similar out-
come proportions to those of Daugherty.
Taking our original cohort of 6045 patients with sim-
ple hypertension and 646 patients with aTRH, allowing
for a loss to follow-up of 10% and applying the propor-
tions of 18 and 13.5%, with a significance level of 0.05,
confirms that the cohort has 80% power to show a
significant difference.
Statistics analysis plan
The primary response is the probability of patients
developing the outcome of interest as defined by
Daugherty. A logistic regression model will be used to
compare the probabilities between the two groups while
adjusting for explanatory variables such as age, gender,
socioeconomic status, baseline blood pressure, presence
of diabetes or kidney disease as appropriate. Initially all
explanatory variables will be included as adjusters, and
the ridge regression and the LASSO [12] will be used to
account for any multicollinearity present among the
explanatory variables. Classification trees will be used to
identify potentially useful interactions.
Results
All three contacted practices agreed to participate. Of
the original 210 patients in these practices, data was
available for 205 patients (97.6%). Five patients had
transferred practice and data was not available (see
Fig. 1). Follow-up was for a median of 23 months. File
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search took place from June 19 to July 14 2017—a total
of 4 weeks for three practices. The total time spent in
data collection at the practices was 44 h which was an
average of 12.6 min per patient.
Table 1 shows the characteristics of the original cohort
(n = 646), and Table 2 illustrates the characteristics of
the 205 patients examined for prognosis. The average
manual BP reading was 138 mmHg (SD19) systolic
blood pressure and 75 mmHg (SD12) diastolic blood
pressure. A mean reduction of 5 mm Hg systolic
(SD11mmHg) is seen between the latest clinic readings
and the original cohort's readings. One hundred twelve
patients (over the previous 23 months median follow-up
period) had ABPM, and the daytime average ABPM
Flow Sheet of participants in Feasibility Study
Entire aTRH Cohort
16  practices; 646 
patients
Feasibility Study
3 practices; 210 
patients 
All practices 
particpated and all 
210 patients 
identified
205/210 patients 
followed up 
17 (8%) had main 
outcome measure
Fig. 1 Flow sheet of participants in the feasibility study
Table 1 Demographic and clinical details for original cross sectional group (n = 646)
Demographic (Mean if applicable) Standard deviation (from mean)
Age (years) 71.1 12
Sex 54% male
Eligible for Primary Care Reimbursement Scheme (marker of household income) 82% (n = 530)
Clinical details
Diabetes 37% (n = 237)
CKD 40% (n = 258)
Cardiac failure 12% (n = 79)
Manual BP 142/78 mmHg 18/12 mmHg
Recent ABPM BP (where available within 6 months) 148/81 mmHg (n = 74) 21/14 mmHg
Medications
No. of anti-hypertensive drugs used 3.7 0.7
4 or more anti-hypertensive drugs 56% (n = 364)
Sub-divisions
True TRH 166
Pseudo-resistant TRH 480
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reading was 136 (SD16)/74 (SD10) mmHg. There were
anti-hypertensive medications and or dose changes in
57%. Nine percent (n = 18) no longer met the minimum
inclusion criteria for aTRH of three or more medica-
tions. Average eGFR increased from 58.8 (SD17.4) to 66
(SD19.7) mls/min/1.73m2. From the 210 patients exam-
ined, 65 persons have true resistant TRH (26%) and 140
persons have pseudo-resistant TRH (Table 2), while
from the main cohort of 646 persons with aTRH, 30%
(n = 166) have true TRH and 70% (n = 480) have pseudo-
resistant TRH (Table 1).
Thirty-five events of interest occurred—the most com-
mon was the new-onset retinopathy at 4.3% (9/210) (see
Table 3). Of the six patients who died, identification of
cause of death was possible from practice records in five;
the national General Register Office was successfully
used for the final patient. Seventeen patients from 210
in the examined cohort (8%) had the main composite
outcome of death or an incident cardiovascular event of
nonfatal myocardial infarction, heart failure, stroke or
CKD. There were 123 admissions recorded in 94 indi-
vidual patients, both day and overnight, and these are
detailed in Table 4.
Discussion
Prior to conducting a larger cohort study of all 646 pa-
tients in all 16 practices, we needed to demonstrate the
feasibility of the proposed methodology by addressing
key uncertainties. Our key uncertainties related to the
acceptability of follow-up to practices, the availability of
outcome data (especially in a health system without uni-
versal registration) and the workload involved. By expli-
citly addressing these uncertainties in a feasibility study,
we can confirm that an adequately powered subsequent
follow-up study of the entire cohort is possible.
We attempted to ensure that the follow-up strategy
imposed little burden on practices, and this appeared to
work well. The average research time of 12 min per
Table 2 Demographic and clinical details for patients with apparent treatment-resistant hypertension in feasibility study (n = 210)
Demographic (Mean if applicable) Standard deviation (from mean)
Age (years) 73.7 YOA 11.2
Sex 56% male
Eligible for Primary Care Reimbursement Scheme (marker of household income) 80% (n = 167)
Clinical details
Diabetes 31% (n = 65)
CKD 41% (n = 87)
Cardiac failure 15% (n = 31)
Manual BP 138/75 mmHg 19/12 mmHg
Recent ABPM BP (where available within 23 months median follow-up period) 134/76 mmHg (n = 112) 16/10 mmHg
Medications
No. of anti-hypertensive drugs used 3.7 1.06
4 or more anti-hypertensive drugs 51%
Subdivisions
True TRH 26% (n = 65)
Pseudo-resistant THR 74% (n = 140)
Table 3 Outcome events for patients with apparent treatment-
resistant hypertension in feasibility study (n = 205)
Any cause of deatha 6
CVD cause death 1
New non-fatal myocardial infarctiona 2
New non-fatal congestive cardiac failurea 5
New non-fatal cerebrovascular accidenta 3
New-onset chronic kidney diseasea 1
New non-fatal transient ischaemic attack 5
New-onset retinopathy 9
New atrial fibrillation 3
New onset peripheral arterial disease 0
Total
Number of events total 35
Number of individuals with composite outcome 17
aThese are included in the main outcome composite outcome (Daugherty)
Table 4 Admissions for patients with apparent treatment-
resistant hypertension in feasibility study (123 events, 94 patients)
Admissions Number (n = 123) Percentage of total
Non-CVD hospitalisations 62 50% (62/123)
Non-CVD day admissions 27 22% (27/123)
CVD hospitalisations 23 19% (23/123)
CVD day admissions 11 9% (11/123)
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patient includes data collection only, but travel to prac-
tices was a mean of 80 min return (maximum trip—2 h
return). The main variation in data collection time be-
tween practices was the number of patient files exam-
ined. The main variation in data collection time between
individual patients was the number of recorded health
care interactions.
Tips for ensuring a smooth research process include
pre-booking time slots for practice computers, showing
flexibility regarding access times; multiple half days may
be available as opposed to full days and administrator/
front desk workload acknowledgement, e.g. teas, cour-
tesy and thank you cards. The signing of individual prac-
tice confidentiality agreements was also seen as
important. These may not be required by local ethics
committees, but GP’s data protection fears are eased by
such. Tips for ensuring accurate data collection include
ensuring the adequate training of researchers in use of
the relevant patient’s data management system and
meeting with practice administrators prior to data col-
lection. Administrators will know where specific data
items are stored, e.g. ABPM reports and how the files of
those who are deceased or have moved on are managed
in individual practices. These issues will need to be fac-
tored into future planning.
All practices that participated were part of a
university-affiliated research network WestREN. Regular
e-mail updates and annual meetings where research pro-
jects were discussed are key to maintaining practice par-
ticipation. Allowing practices to fulfil their mandatory
audit commitments, while participating in research pro-
jects, is also welcome. The very low numbers lost to
follow-up and completeness of data are pleasing; how-
ever, this may not be replicated in the larger level, and
due allowance has been made in the power calculation.
Outcome measurement data appeared readily avail-
able. Coding of individual consultations is not common
in Irish general practice. A combination of coding for
the key diagnoses of interest by practices, together with
review of scanned written hospital discharges, while
time-consuming, appeared to overcome this challenge.
In the last 5 years, public hospitals in the region have
introduced electronic discharge summaries which auto-
matically enter the individual patient electronic record,
significantly aiding the outcome assessment process.
Identification of cause of death from practice data also
appeared straightforward with only one of six deaths
requiring access to the online State Register. This was
needed for an in-hospital patient death, where cause of
death was unclear from practice clinical notes and notice
of death, as opposed to cause of death, was recorded.
Two outcome measurements were of particular
interest. New-onset retinopathy has not been reported
in other similar cohort studies. It was our most
common outcome event. With over a third of our
patients with apparent resistant hypertension having
diabetes, this is of potential significance. Consider-
ation may need to be given to including retinopathy
in any composite outcome measurement. It highlights
the importance of the work of the COMET (Core
Outcomes Measures in Effectiveness Trials) group
who are agreeing standardised sets of outcomes
(http://www.comet-initiative.org). There is, as yet, no
agreed core outcome set in the study of resistant hyper-
tension. Contrary to our expectations, renal function as
estimated by eGFR, improved rather than deteriorated
over the duration of follow-up. Clearly, our sample size
limits the interpretation of this. However, it does empha-
sise the need for serial eGFR measurements to be utilised
rather than ‘once off ’ recordings.
Comparison with other work
Table 5 illustrates the key parameters of previous studies
reviewing the prognosis of patients with aTRH. Our
study is distinguishable as both the only study based in
general practice and the only study to have individual
patient record review. This facilitates consideration of
dosing, adherence and white coat hypertension which
are often overlooked in other studies. Similar to
Daugherty, we will be able to, with adequate power,
compare outcomes for patients with simple hypertension
to those with treatment-resistant hypertension (Table 2).
However, the numbers with true resistant hypertension
will be small making meaningful comparisons difficult.
Strengths and limitations
We based our methodology on a previous cohort study
we conducted in the region which followed up 1605
patients with heart disease from 35 practices after 5 years
[13]. This experience was invaluable in developing our
protocol. The subsequent introduction of automatic
hospital electronic discharges and enhanced coding by
practices has aided cohort study conduct.
There are four significant limitations. Firstly, on balance,
a non-random selection of practices was preferred as it
allowed us to sample the diversity of practice size and loca-
tion. We used three typical practices. It also facilitated
transport issues for researchers, within a short available
time period, to be taken into account. Other practices may
have specific issues which we have not encountered, but
the recording of electronic health care data is similar in the
Socrates® practice software system, which is reassuring.
Secondly, the Irish health system is a complex amal-
gam of private and public providers. Other similar stud-
ies (Daugherty [5], Irvin [7]) had the significant benefits
of an integrated health system facilitating collection of
primary, secondary and tertiary care data. We can never
be sure that some important outcome data is not
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missing. Thirdly, we did not follow up the five patients
who transferred practice. This may be the main chal-
lenge in the future and will likely involve locating
patients who have moved practice. These patients may
subsequently have their data now recorded in an alterna-
tive electronic format. Consideration in the full cohort
study to providing resources to do this is appropriate.
Finally, the cohort was assembled in a cross-sectional
study and not as an incident cohort with no recorded
date of diagnosis.
Conclusions
This study demonstrates that the proposed method-
ology for a full cohort study within general practice of
patients with apparent treatment hypertension is both
acceptable to practices and feasible. An adequately
powered subsequent follow-up study of the entire
cohort appears possible.
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